Quantbot Technologies LP Buys 193 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quantbot Technologies LP lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1,754.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 204 shares of the biopharmaceutical company’s stock after purchasing an additional 193 shares during the quarter. Quantbot Technologies LP’s holdings in Alnylam Pharmaceuticals were worth $56,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ALNY. Diversified Trust Co bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $1,210,000. Los Angeles Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares in the last quarter. Breakwater Capital Group bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $249,000. Sanctuary Advisors LLC acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $578,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Alnylam Pharmaceuticals by 22.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock valued at $20,165,000 after acquiring an additional 13,422 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ALNY shares. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Piper Sandler reiterated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $256.26 on Friday. The company’s 50 day moving average price is $269.12 and its two-hundred day moving average price is $245.29. The stock has a market cap of $33.05 billion, a P/E ratio of -97.81 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.15 earnings per share. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. This represents a 8.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,370 shares of company stock worth $2,100,703 over the last three months. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.